Preview

Rational Pharmacotherapy in Cardiology

Advanced search

EFFICACY AND SAFETY OF BISOPROLOL IN YOUNG MEN WITH ARTERIAL HYPERTENSION AND OBESITY

https://doi.org/10.20996/1819-6446-2011-7-2-193-198

Full Text:

Abstract

Aim. To evaluate effect of bisoprolol on circadian blood pressure (BP) profile, autonomic cardiovascular regulation, lipid and carbohydrate metabolism in young patients with arterial hypertension (HT) and obesity. Materials and methods. 36 men aged 18 to 35 years with HT 1-2 degrees, obesity 1-2 degrees and signs of sympathetic over activity were examined. In addition to standard clinical examination assessment of heart rate variability (HRV) during orthostatic test with spectral analysis, ambulatory BP monitoring, evaluation of lipid profile, oral glucose tolerance test, determination of immunoreactive insulin, insulin resistance index and functional activity of beta-cells were performed. Anthropometric measurements included body mass index and waist circumference. Bisoprolol in the initial dose of 5 mg QD orally for 12 weeks was assigned to all patients. After 12 weeks of bisoprolol treatment repeated examination was performed. Results. Significant changes in HRV after 12 weeks of treatment with bisoprolol was found. Parasympathetic influence of autonomic nervous system increased during orthostatic test. Contribution of the slow and very slow waves, which reflect sympathetic and neurohumoral activity , reduced. Total spectral power was significantly increased. Initial tachycardia reduced. Target BP values were achieved after 12 weeks of treatment with bisoprolol 5 mg QD. Increase in a number of dippers and decrease in a number of nondippers in terms of both systolic and diastolic BP was observed. Heart rate and HRV was significantly decreased. No adverse events in terms of lipid or carbohydrate metabolism were found during treatment with bisoprolol. Conclusion. Bisoprolol 12 week treatment resulted in sympathetic activity decrease and parasympathetic activity increase, achievement of BP target levels, improvement of BP circadian profile. Bisoprolol therapy in dose of 5 mg/day demonstrated metabolic neutrality in patients with risk factors of cardiovascular diseases and type 2 diabetes.

About the Authors

A. G. Avtandilov
Russian Medical Academy of Postgraduate Education
Russian Federation


I. I. Esenova
I.M. Sechenov First Moscow State Medical University
Russian Federation


S. L. Petrosov
Russian Medical Academy of Postgraduate Education
Russian Federation


References

1. Zimmet P., Alberti K.G., Kaufman F. et al. The metabolic syndrome in children and adolescents - an IDF consensus report. Pediatr Diabetes 2007;8(5):299-306.

2. Julius S., Krause L., Schork N. et al. Hyperkinetik borderline hypertension in Tecumsen, Michigan. J Hypertens 1991; 9(1): 77–84.

3. Facchini F., Chen Y., Clinkinbeard C. Insulin resistance, hyperinsulinemia, and dyslipidemia in nonobese individuals with a famili history of hypertension. Am J Hypertens 1992; 5: 694–9.

4. Vertkin A.L., Arinina E.N., Morgunov L.Yu. et al. Sexual health kardiopatsienta: new insights and real help. Meditsinskiy sovet 2007; 1: 36-40. Russian (Верткин А.Л., Аринина Е.Н., Моргунов Л.Ю. и др. Сексуальное здоровье кардиопациента: новые представления и реальная помощь. Медицинский совет 2007; 1: 36-40).

5. Matthews D.R., Hosker J.P., Rudenski A.S. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28(7):412-9

6. Balabolkin M.I., Klebanova E.M., Kreminskaya V.M. Treatment of diabetes and its complications: a tutorial. Moscow: OAO Meditsina; 2005 Балаболкин М.И., Клебанова Е.М., Креминская В.М. Лечение сахарного диабета и его осложнений: учебное пособие. М.: ОАО Медицина; 2005.

7. Moiseev V.S., editor. Monitoring of blood pressure: methodological aspects and clinical significance. Moscow; 1999. Russian (Моисеев В.С., редактор. Мониторирование арте-риального давления: методические аспекты и клиническое значение. М.;1999).

8. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28: 1039-1057.

9. Maggioni A.P., Sinagra G., Opasich C. et al. Betablockers in patients with congestive heart failure: guided use in clinical practice Investigators. Treatment of chronic heart failure with beta adrenergic blockade beyond controlled clinical trials: the BRING-UP experience. Heart 2003; 89(3): 299–305.

10. Martsevich S.Yu. Beta-blockers. In: Belenkov Yu.N., Oganov R.G., editors. Cardiology. National guidelines. Moscow: GEOTAR-Media; 2007: 377–395. Russian (Марцевич С.Ю. Бета-адреноблокаторы. В: Беленков Ю.Н., Оганов Р.Г., редакторы. Кардиология. Национальное руководство. М.: ГЭОТАР-Медиа; 2007: 377–395).

11. Dianov O.A., Gnusaev S.F., Ivanov D.A. et al. Violation of the functional state of the cardiovascular system and metabolism in obese children. Pediatriya 2007;86(3): 32-34. Russian (Дианов О.А., Гнусаев С.Ф., Иванов Д.А. и др. Нарушение функционального состояния сердечно-сосудистой системы и метаболизма у детей с ожирением. Педиатрия 2007;86(3): 32-34).

12. Ostroumova O.D. Possible applications of highly selective b-blockers in patients with concomitant diseases. Russkiy meditsinskiy zhurnal 2004; 12: 721–725. Russian (Остроумова О.Д. Возможности применения высокоселективных b-блокаторов у больных с сопутствующими заболеваниями. Русский медицинский журнал 2004; 12: 721– 725).

13. Mikhaylova I.E. Bisoprolol: pharmacological properties and clinical application. Russkiy meditsinskiy zhurnal 2004;4:225-231. Russian (Михайлова И.Е. Бисопролол: фармакологические свойства и клиническое применение. Русский медицинский журнал 2004;4:225-231).

14. Carlberg B., Samuelsson O., Lindholm L.H. Atenolol in hypertension: is it a wise choice? Lancet 2004; 364: 1684–1689.

15. Lindholm L.H., Carlberg B., Samuelsson O. Shoud beta-blockers first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545–1552.

16. Khan N.A., McAlister F.A., Rabkin S.W. et al. The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - Therapy. Can J Cardiol 2006;22(7):583-93.


For citation:


Avtandilov A.G., Esenova I.I., Petrosov S.L. EFFICACY AND SAFETY OF BISOPROLOL IN YOUNG MEN WITH ARTERIAL HYPERTENSION AND OBESITY. Rational Pharmacotherapy in Cardiology. 2011;7(2):193-198. (In Russ.) https://doi.org/10.20996/1819-6446-2011-7-2-193-198

Views: 1104


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)